Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

Search


Order results by:     
 
Issue Title
 
Vol 8, No 4 (2015) THE COST OF NUTRITION ALTERNATIVES FOR PREMATURE INFANTS IN RUSSIA Abstract  similar documents
K. V. Gerasimova, M. V. Avxentyeva, I. A. Belyaeva
"... breastfeeding. Methods. The cost of providing 100 ml of breast milk (BM) using clinical breast pump and 100 ml ..."
 
Vol 11, No 2 (2018) Economic evaluation of postoperative hypofractionated radiation therapy in patients with breast cancer Abstract  similar documents
G. V. Afonin, Yu. A. Ragulin, M. V. Avxentyeva, I. A. Gulidov, S. A. Ivanov, A. D. Kaprin
"... the treatment costs in patients with breast cancer while maintaining a high treatment efficacy and quality ..."
 
Vol 12, No 4 (2019) Pharmacoeconomic analysis of using cyclin-dependent kinase 4 and 6 inhibitors in the first line treatment of HR-positive HER2-negative advanced breast cancer Abstract  similar documents
N. A. Avxentyev, E. V. Lubennikova, M. Yu. Frolov
"... considered. Results. Mean direct medical costs of using palbociclib + letrozole were 2 082 333 RUB per ..."
 
Vol 9, No 1 (2016) COST-EFFECTIVENESS ANALYSIS OF BRENTUXIMAB VEDOTIN IN ADULTS WITH RELAPSED OR REFRACTORY HODGKIN’S LYMPHOMA Abstract  similar documents
G. R. Khachatryan, D. V. Fedyaev, M. V. Avxentyeva, V. S. Dombrovskiy
"... is an appropriate alternative as ICER per LY is lower than for standard treatment Ch ± RT + alloSCT vs Ch ± RT. Cost ..."
 
Vol 10, No 2 (2017) COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA Abstract  similar documents
N. L. Pogudina, E. G. Kosolapov, F. S. Kochenkov, A. V. Karaulov, N. L. Bondarenko, D. V. Blinov
"... / formoterol by vilanterol / fluticasone furoate are 1,151,512,731 RUR per 100,000 patients. Conclusion ..."
 
Vol 12, No 4 (2019) Comparative clinical and economic analysis of using SYSADOA drugs containing chondroitin sulphate or influencing its biosynthesis in the treatment of patients with stage II knee osteoarthritis Abstract  similar documents
I. V. Sarvilina, A. N. Galustyan, A. K. Hadzhidis, I. S. Sardaryan, N. V. Lavrov, O. A. Gromova, Yu. S. Prokofieva
"... & Lawrence classification. We calculated the cost-effectiveness from the direct costs and treatment ..."
 
Vol 10, No 4 (2017) PHARMACOECONOMIC JUSTIFICATION OF A WIDER USE OF PREVENTIVE HEMOPHILIA THERAPY IN THE RUSSIAN FEDERATION Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... and 2 do not exceed one GDP per capita, and the technologies are cost-effective. Conclusion. In both ..."
 
Vol 12, No 4 (2019) Evolution of healthcare provider payment mechanisms Abstract  similar documents
V. V. Omelyanovskiy, N. N. Sisigina, V. K. Fedyaeva, N. Z. Musina
"... the societal demands (greater access to health services, cost reduction, and better quality) and prevent “moral ..."
 
Vol 9, No 4 (2016) THE COSTS OF REGIONAL ANESTHESIA WITH THE USE OF LEVOBUPIVACAINE, RACEMIC BUPIVACAINE AND ROPIVACAINE Abstract  similar documents
G. E. Ulrikh, A. V. Rudakova
"... levobupivacaine allows you to reduce costs 29.6-56.9 per cent compared with bupivacaine and ropivacaine. Taking ..."
 
Vol 11, No 1 (2018) Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia Abstract  similar documents
I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina
"... to the reproduced AA (up to 100% replacement of reference  medications), the costs would remain to be higher than ..."
 
Vol 11, No 2 (2018) Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia Abstract  similar documents
I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina
"... . For the «number of hospitalization-free days per year», the use of AA was more cost-effective only versus the 100 ..."
 
Vol 11, No 4 (2018) International experience in determining the cost-effectiveness thresholds Abstract  similar documents
T. P. Bezdenezhnykh, N. Z. Musina, V. K. Fedyaeva, T. S. Tepcova, V. A. Lemeshko, V. V. Omelyanovsky
"... the presence of HTA systems. The CeT is expressed as additional cost per unit of incremental health benefit ..."
 
Vol 12, No 3 (2019) Comorbidity in elderly patients with atrial fibrillation affects the “cost of illness” Abstract  similar documents
S. V. Malchikova , N. S. Maksimchuk-Kolobova, M. V. Kazakovtseva 
"... .8 medications. Direct costs amounted to 18298.2±9440.4 RUB per patient with AF per year. Of this amount, 78 ..."
 
Vol 5, No 1 (2012) COST OF ILLNESS ANALYSIS: TYPES, METHODOLOGY, RUSSIAN SPECIFICS Abstract  similar documents
R. I. Yagudina, I. Yu. Zinchuk, M. M. Litvinenko
"... Cost of illness is one of the basic methods of pharmacoeconomical estimation and in substance ..."
 
Vol 6, No 3 (2013) PHARMACOECONOMIC ANALYSIS OF DOCETAXEL IN THE ADJUVANT THERAPY OF BREAST CANCER Abstract  similar documents
R. I. Yagudina, I. Yu. Zinchuk
"... it was determined that for 10-years horizon cost rate for the treatment of one patient with breast cancer will be 1 ..."
 
Vol 9, No 2 (2016) METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY Abstract  similar documents
N. A. Avxentyev, E. V. Derkach, E. A. Pyadushkina, M. D. Ter-Ovanesov
"... per patient medication costs of using regorafenib are 255,000 rubles, which is 104,000 rubles less ..."
 
Vol 6, No 4 (2013) Pharmacoeconomic analysis of fluid therapy in the treatment of patients with peritonitis Abstract  similar documents
R. I. Yagudina, M. M. Murashko
"... and Sterofundin drugs were compared during the analysis. A cost analysis, cost-effectiveness analysis, budget ..."
 
Vol 7, No 1 (2014) ECONOMIC ASSESSMENT OF MAGNESIUM DEFICIENCY CORRECTION FOR BASIC THERAPY EFFICACY OF UNCONTROLLED ASTHMA IN CHILDREN Abstract  similar documents
V. I. Petrov, I. N. Shishimorov, O. V. Magnitskaya, Ju. V. Ponomareva
"... the cost of achieving control and cost per symptom-free day after 12 and 24 weeks of therapy ..."
 
Vol 7, No 3 (2014) ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION Abstract  similar documents
M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentyeva
"... per year: average-weighted costs per one child with Mucopolysaccharidoses type VI amounted to 40 ..."
 
Vol 12, No 4 (2019) Crucial areas of the economic analysis of public cancer care Abstract  similar documents
D. A. Andreev, K. I. Polyakova, A. A. Zavyalov, T. N. Ermolaeva, A. G. Fisun, A. D. Ermolaeva, V. A. Dubovtseva, T. E. Maksimova
"... cancer care for Moscow residents. The aim of this study was to identify the crucial areas of the cost ..."
 
Vol 9, No 1 (2016) COMPARATIVE CLINICAL AND ECONOMIC ANALYSIS OF THE INTENSIFICATION THERAPY IN PATIENTS WITH UNCONTROLLED DIABETES TYPE 2 USING BASAL INSULIN OR DAPAGLIFLOZIN Abstract  similar documents
V. I. Petrov, S. V. Nedogoda, M. Yu. Frolov, A. S. Salasyuk, I. N. Barykina, V. O. Smirnova, V. Yu. Khripaeva
"... according to standard pharmacoeconomic methods: cost-utility analysis (CUA), budget impact analysis (BIA ..."
 
Vol 10, No 2 (2017) COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD Abstract  similar documents
E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov, N. L. Bondarenko, A. V. Karaulov
"... (a difference of 24%). The average direct medical costs were 32,753 and 41,333 rubles per patient per year ..."
 
Vol 9, No 3 (2016) DRUGS PROVIDED TO BREAST CANCER PATIENTS WITHIN THE STATE PROGRAMS OF DRUG SUPPLY Abstract  similar documents
M. V. Avxentyeva, V. I. Bogin, E. V. Derkach, V. V. Omelyanovskiy, M. B. Stenina, A. V. Tarakanov, M. Yu. Frolov
"... The purpose of our research was to analyze the actual practice of medicine in patients with breast ..."
 
Vol 10, No 3 (2017) Evaluation of economic damage from multiple sclerosis in the city of Ufa, Russia Abstract  similar documents
E. V. Ivanova, K. Z. Bachtiyarova
"... and premature mortality (indirect costs). Results. Because of MS only in the city Ufa, the Russian economy loses ..."
 
Vol 9, No 1 (2016) PHARMACOECONOMIC STUDY OF LENVIMA (LENVATINIB) IN ADVANCED PROGRESSIVE RADIO IODINE REFRACTORY DIFFERENTIATED THYROID CANCER IN THE RUSSIAN FEDERATION Abstract  similar documents
M. Yu. Frolov, V. A. Rogov
"... providing in the proposed model, 1628 additional years of life for patients per 5 years. Additional costs ..."
 
Vol 11, No 2 (2018) Clinical and economic efficiency of the loop ileostomy closure by various methods Abstract  similar documents
A. V. Veselov, S. I. Achkasov, O. I. Sushkov, A. I. Moskalev, I. S. Lantsov
"... for the anastomosis formation. Results. The average cost of the treatments (per patient) in groups 1 and 2 was 131 ..."
 
Vol 11, No 3 (2018) Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus Abstract  similar documents
A. G. Tolkushin, N. L. Pogudina
"... rubles vs 2.88 million rubles were indirect medical costs) on average per patient in the belimumab group ..."
 
Vol 6, No 3 (2013) COST-UTILITY ANALYSIS OVER USE OF TYROSINE KINASE INHIBITORS (TASIGNA AND GLEEVEC) FOR TREATMENT OF CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AS FIRST-LINE THERAPY FOR DE NOVO PATIENTS Abstract  similar documents
R. I. Yagudina, A. Yu. Kulikov, I. A. Komarov
"... incidence is about 1-2 cases on 100 000 men annually. Pharmacoeconomic evaluation of this pathology ..."
 
Vol 10, No 1 (2017) PERAMPANEL EFFECTIVENESS IN THE TREATMENT OF REFRACTERY PARTIAL ONSET EPILEPSY WITH OR WITHOUT SECONDARY GENERALIZATION: PHARMACOECONOMIC ANALYSIS FOR THE RUSSIAN FEDERATION HEALTH CARE SYSTEM Abstract  similar documents
N. K. Mazina, I. V. Sheshunov, P. V. Мazin, Yu. V. Kislitsin, E. M. Markova
"... . Conclusion. Direct costs modeling was performed to estimate annual expenses (per patient) of the adjunctive ..."
 
Vol 5, No 2 (2012) METHODOLOGY OF COST-UTILITY ANALYSIS IN PHARMACOECONOMICSTUDIES Abstract  similar documents
R. I. Yagudina, I. V. Sorokovikov
"... pharmacoeconomic cost-utility analysis – CUA is at third place by popularity (10% of studies ..."
 
Vol 7, No 3 (2014) MODELI NG CLINICAL AND ECONOMIC OUTCOMES OF TESTING FOR LTBI WITH T-SPOT.TB IN IMMUNOCOMPROMISED CHILDREN Abstract  similar documents
V. I. Ignatyeva, M. V. Avxentyeva, V. V. Omelyanovsky, G. R. Khachatryan
"... was possible in 2 cases. The total costs per cohort were 1.71 mln RUR. in case of TST testing (including ..."
 
Vol 8, No 4 (2015) CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS Abstract  similar documents
E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva
"... for the cost-minimization analysis (model 1) and analysis of the budget impact TRA usage (model 2 ..."
 
Vol 5, No 2 (2012) THE ANALYSIS OF COST OF ILLNESS OF PREGNANT WOMEN WITH SYPHILIS Abstract  similar documents
A. I. Ovod, M. D. Mukovnina
 
Vol 12, No 1 (2019) Individual cost accounting in the management of medical organizations Abstract  similar documents
I. A. Zheleznyakova, L. A. Kovaleva, T. A. Khelisupali
"... In the modern economic conditions, the rational planning of costs and the complex process ..."
 
Vol 8, No 4 (2015) PHARMACOECONOMIC EVALUATION OF INFLUENZA AND PNEUMOCOCCAL VACCINATION IN EMPLOYEES OF THE JOINT STOCK COMPANY "RUSSIAN RAILWAYS" (JSCO "RZD") ON INVESTMENT FOR THE EMPLOYER Abstract  similar documents
D. A. Zhukov
"... statistical software was not used). The author presented the method of direct and indirect costs calculation ..."
 
Vol 7, No 1 (2014) ABC END VEN ANALYSYS OF COSTS FOR MEDICINE SAND MEDICAL TREATMENT COSTS PATIENT Abstract  similar documents
M. A. Shapovalova, L. R. Koretskaya
"... of pharmacotherapy and medical services in the department of neurology. An assessment of the costs of hospitalization ..."
 
Vol 7, No 3 (2014) THE ANALYSIS OF METHODOLOGIC CHARACTERISTICS OF RESEARCHES ON SOCIAL AND ECONOMIC BURDEN OF DISEASES IN RUSSIA IN THE FRAMES OF DEVELOPMENT OF STANDARD COST OF ILLNESS METHODOLOGY FOR THE HEALTH TECHNOLOGY ASSESSMENT Abstract  similar documents
V. I. Ignatyeva, M. V. Avxentyeva
"... there are no uninamioulsly accepted methods and approaches for this type of research. The cost of illness method (assessment ..."
 
Vol 12, No 3 (2019) Pharmacoepidemiological analysis of antimicrobial therapy for burn injury in the hospital settings Abstract  similar documents
O. V. Zhukova, E. S. Nekaeva, E. S. Khoroshavina, E. A. Kozlova, Yu. A. Dudukina, I. Yu. Arefyev
"... and discussion. For antimicrobial agents of interest, the NDDD (Number of DDD) per year, and the NDDD/100 bed ..."
 
Vol 8, No 2 (2015) REVIEW OF THE INTERNATIONAL PRACTICE OF COST-SHARING MECHANISM IN NATIONAL HEALTH CARE SYSTEMS Abstract  similar documents
Natalia Nikolayevna Sisigina, Vitalii Vladimirovich Omel'yanovskii, Nikolay Alexandrovich Avxentyev
"... The article gives a review of international experience of using of cost-sharing mechanism ..."
 
Vol 10, No 2 (2017) COSTS OF ANTIRETROVIRAL DRUGS USED IN THE THERAPY OF HIV-INFECTED PATIENTS: A PHARMACOECONOMIC ANALYSIS Abstract  similar documents
M. B. Kubaeva, Y. Sh. Guchshina
"... The aim of our study was to conduct a pharmacoeconomic and cost analysis of the therapeutic use ..."
 
Vol 10, No 2 (2017) COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD Abstract  similar documents
E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov
"... ) was used as the main criterion of effectiveness. Direct medical costs of drug therapy, and the costs ..."
 
Vol 11, No 2 (2018) Introduction of medical products into healthcare practice and costs reimbursement: European experience Abstract  similar documents
V. V. Omelyanovsky, S. S. Otstavnov, N. Z. Musina, V. S. Dombrovskii
 
Vol 11, No 4 (2018) Costs of pharmacotherapy in pediatric patients with community-acquired pneumonia: mathematical and statistical analysis Abstract  similar documents
I. A. Narkevich, O. D. Nemyatyh, D. D. Siukaeva, I. V. Pavlushkov, D. O. Ivanov, Ya. V. Panyutina
"... for the evaluation of pharmacotherapy costs in pediatric inpatients diagnosed with community-acquired pneumonia ..."
 
Vol 12, No 4 (2019) Clinical and economic analysis of drug costs in a general hospital in 2014-2018 Abstract  similar documents
A. T. Burbello, A. S. Fedorenko, E. L. Latariya, M. V. Pokladova, K. A. Zagorodnikova
"... and costs of the purchased drugs as well as their current consumption by various clinical departments ..."
 
Vol 8, No 2 (2015) PHARMACOECONOMIC STUDIES TREATMENT OF PATIENTS WITH INJURIES IN THE DEPARTMENT OF ANESTHESIOLOGY AND RESUSCITATION WITH METHODS ANALYSIS THE COST OF ILLNESS Abstract  similar documents
Anton Alexandrovich Kasatkin
"... of analysis of the cost of the disease, including the payment of medical costs for medical services, medicines ..."
 
Vol 8, No 2 (2015) ASSESSMENT OF ECONOMIC EFFICIENCY OF APPLICATION OF RALTEGRAVIR BY PATIENTS WITHOUT EXPERIENCE OF TYPE 1 HIV INFECTION THERAPY IN RUSSIA Abstract  similar documents
Elamin H. Elbasha, Elena Aleksandrovna Pyadushkina, Maria Vladimirovna Avxentyeva, Alexander Gennadievich Tolkushin, Maxim Yurievich Frolov
"... The purpose of the work performed was assessment of cost efficiency of Raltegravir within ..."
 
Vol 5, No 3 (2012) CLINICAL AND ECONOMIC BENEFITS OF HUMAN INSULIN ANALOGUESUSE Abstract  similar documents
E. E. Arinina, M. A. Rashyd
"... ®) were 21774 rubles per patient/year, while the cost of an averted severe hypoglycemia was 24728 rubles ..."
 
Vol 5, No 3 (2012) PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER Abstract  similar documents
A. U. Kulikov
 
Vol 11, No 3 (2018) Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies Abstract  similar documents
T. S. Teptsova, T. P. Bezdenezhnyh, V. K. Fedyaeva, N. Z Musina, G. R. Hachatryan, V. V. Tarasov
"... is an empirical assessment of the cost-effectiveness threshold that reflects the utmost productivity of the health ..."
 
Vol 5, No 1 (2012) PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION Abstract  similar documents
R. Yagudina, A. Kulikov, B. Misikova
 
1 - 50 of 144 Items 1 2 3 > >> 

Search tips:

  • Search terms are case-insensitive
  • Common words are ignored
  • By default articles containing any term in the query are returned (i.e., OR is implied)
  • Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
  • Combine multiple words with AND to find articles containing all terms; e.g., education AND research
  • Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
  • Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
  • Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)